This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

United-Guardian Reports Record Earnings

HAUPPAUGE, N.Y., May 9, 2013 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (Nasdaq:UG) reported today that earnings for the first quarter of 2013 set a new company record of $1,564,649 ($0.34 per share), a 27% increase over the first quarter of 2012. Sales for the quarter increased to $3,952,161, a 1.6% increase over last year's first quarter and just short of the company's previous record quarterly sales of just over $4 million.

"We are very pleased with our first quarter results, especially considering that we were able to attain this record earnings level without any sales of our largest pharmaceutical product, Renacidin ® Irrigation," stated Ken Globus, President of United-Guardian. "That product has been unavailable since August 2012 due to manufacturing problems experienced by our supplier. We hope to have that situation remedied and the product back on the market this year, which should give our pharmaceutical sales a significant boost. We are also very pleased that sales of our personal care products increased 14% over last year's first quarter, and sales of our medical and industrial products were both up as well. We are optimistic that sales of our new "Lubrajel Natural" line of natural water-based moisturizers will start to bring in additional revenue by the end of this year. We also will be devoting some of our R&D efforts towards developing new lower-cost forms of Lubrajel that will enable us to expand our sales into geographic markets not currently suitable for our higher-end Lubrajel products."

United-Guardian is a manufacturer of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products.

NOTE: This press release contains both historical and "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company's expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the "safe harbor" provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company's business please refer to the company's reports and filings with the Securities and Exchange Commission.

RESULTS FOR THE QUARTERS ENDED
MARCH 31, 2013 and MARCH 31, 2012*
     
  THREE MONTHS ENDED
   MARCH 31,  
     
  2013 2012
     
Net sales  $ 3,952,161  $ 3,888,692
     
Costs and expenses:    
 Cost of sales 1,411,156 1,539,840
 Operating expenses 561,568 602,863
 Total costs and expenses 1,972,724 2,142,703
     
   Income from operations 1,979,437 1,745,989
     
Other income:    
 Investment income 54,182 69,591
 Gain on sale of asset  --- 2,750
 Income from damage settlement 292,830 ---
 Total other income 347,012 72,341
     
 Income before income taxes 2,326,449 1,818,330
     
Provision for income taxes 761,800 589,700
     
 Net income  $ 1,564,649  $ 1,228,630
     
Earnings per common share (Basic and Diluted)  $ 0.34  $ 0.27
     
Weighted average shares – basic and diluted 4,596,439 4,596,439
     
* More detailed financial information can be found at the company's web site at www.u-g.com.
CONTACT: Robert S. Rubinger
         Public Relations
         (631) 273-0900

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs